Slide 1. Slide 2 Disclosures. Slide 3 Learning Objectives. Catheter-Related Thrombosis and Infection: Reducing Controllable Risk Factors
|
|
- Eustace Wilkinson
- 6 years ago
- Views:
Transcription
1 Slide 1 Catheter-Related Thrombosis and Infection: Reducing Controllable Risk Factors Thomas P. Nifong, MD Vice President, Clinical Operations Metamark Genetics, Inc Cambridge, Massachusetts USA Slide 2 Disclosures 1. Dr. Nifong has received honoraria and consulting fees from Teleflex 2. Dr. Nifong has received honoraria from AngioDynamics 2 Slide 3 Learning Objectives 1. Understand the basic pathophysiology and clinical significance of upper extremity thrombosis. 2. Recall the controllable risk factors associated with catheterrelated thrombosis. 3. Explain how thrombosis and infection interact in central venous catheters 4. Know how new technologies will play a role in reducing catheter-related complications. 3
2 Slide 4 Venous Thromboembolism Incidence of UE-DVT (1-2% that of LE) Primary UE-DVT due to stress or ideopathic is rare: 2 per 100,000 Secondary UE-DVT was previously considered to be rare, but is now not uncommon in hospitalized patients 4 Slide 5 Hemostasis Coagulation system Activated clotting factors & cofactors Thrombin generation Anticoagulant system Coagulation inhibitors & cofactors Thrombin inhibition Blood clot Fibrinolytic system 5 Slide 6 Pathogenesis of Thrombosis Rudolph Virchow STASIS VTE Risk Factors: PC, PS, AT Deficiency Factor V Leiden Prothrombin G20210A VASCULAR INJURY CAD Risk Factors: Hyperlipidemia HYPERCOAG- ULABILITY Tobacco Diabetes 6 Hypertension Family history
3 Slide 7 Prophylaxis in Cancer Carrier M, et al. Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials. J Thromb Haemost 2007; 5: Clinicians are recommended to NOT use either prophylactic doses of LMWH (Grade 1B) or mini-dose warfarin (Grade 1B) to try to prevent catheter-related thrombosis for cancer patients receiving chemotherapy or hormonal therapy or with indwelling central venous catheters. Hirsh J, Guyatt G,Albers GW, Harrington R, and Schunemann HJ. Executive Summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 Jun;133:71S- 109S. 7 Slide 8 Catheters and Thrombosis: Controllable Risk Factor Insertion site Femoral vein vs. Subclavian vein vs. Internal Jugular vein vs. PICC Catheter type, size, tip location Endothelial damage Traumatic insertion Tip location Catheter size and rigidity Venous stasis Catheter size relative to vein size Catheter material 8 Slide 9 9 CVC-related Thrombosis Study Type Detection Thrombosis Cimochowski Schillinger Wilkin Trerotola Merrer Timsit Prospective (acute HD) Prospective (acute HD) Asymptomatic Venogram IJ: 0% SC: 50% Asymptomatic Venogram IJ: 10% SC: 42% Prospective Asymptomatic Doppler US IJ: 25.9% (longitudinal HD) Retrospective (tunneled) Prospective Randomized (ICU) Prospective (ICU) Symptomatic Clinical with US or venogram IJ: 3% SC: 13% Asymptomatic Doppler US Femoral: 21.5% SC:1.9% Asymptomatic Doppler US IJ: 41.7% SC: 10.5%
4 Slide 10 PICC-related Thrombosis Study Type Detection Thrombosis Ng Prospective Symptomatic Clinical with US 1.6% confirmation Ultrasound Grove Retrospective Presumed 3.9% Symptomatic Chemaly Retrospective Presumed US or Venogram 2.5% Symptomatic King Retrospective Symptomatic Clinical with US 2.0% confirmation Clinical with Lobo Retrospective Symptomatic US 4.9% confirmation DVT or PE Cowl Prospective Symptomatic Clinical with US 7.8% confirmation (PICC vs. SC) Gonsalves Retrospective Asymptomatic US central veins 7.0% only Abdullah Prospective Asymptomatic Venogram 38.5% Allen Retrospective Asymptomatic Venogram 23.3% 10 Slide 11 PICC-related symptomatic SVT versus DVT Liem TK et al: Peripherally inserted central catheter usage patterns and associated symptomatic upper extremity venous thrombosis. J Vasc Surg; 2012 Retrospective study: All UE venous duplex scans during a 12- month period were reviewed, selecting patients with isolated SVT (219) or DVT (154) and PICCs placed 30 days (2,056) Results: Rates for PICC-SVT (44) were 1.9% for basilic, 7.2% for cephalic, and 0% for brachial vein PICCs Rates for PICC-DVT (54) were 3.1% for basilic, 0% for cephalic, and 2.2% for brachial vein PICCs 11 Slide 12 Laterality of PICC line placement Sperry BW, Roskos M, Oskoui R: The effect of laterality on venous thromboembolism formation after peripherally inserted central catheter placement. J Vasc Access; 2012 Jan-Mar;13(1):91-5 Retrospective study of 798 PICC placements (568 right-sided and 230 left-sided placement Results: VTE rate right-sided: 1.23% vs left-sided: 1.30% Marnejon T, Angelo D, Abu Abdou A, Gemmel D: Risk factors for upper extremity venous thrombosis associated with peripherally inserted central venous catheters. J Vasc Access; 2012 Apr-Jun;13(2):231-8 Retrospective study of 400 consecutive patients with PICC placements Results: Left-sided PICC line sites posed a greater risk (P=.026) 12
5 Slide 13 Is Upper Extremity Thrombosis Clinically Important? 13 Copyright. Gray's Anatomy of the Human Body Slide 14 Study Patients Findings Monreal et al. Thrombosis and Haemostasis Lobo B, et al. Journal of Hospital Medicine 2009 Fletcher, et al. Neurocrit Care 2011 Ong B, et al. Australasian Radiology patients with PICC or SC catheter-related DVT 777 patients with PICC lines (38 patients with VTE) 479 PICC lines placed in neuro ICU (39 patients with DVT) 76 patients with PICCrelated DVT VQ scan showed PE in 15.3% Symptomatic PE in 1% of patients Symptomatic PE in 1.3% of patients (15% of patients with DVT) Post-thrombotic sequelae w/25% mild pain, 2% moderate pain, 15% arm edema Slide 15 Treatment Conservative management along with catheter removal appropriate for basilic, brachial, and cephalic vein thrombosis Recurrence or extension may warrant anticoagulation Catheter removal may lead to PE Axillary vein and above requires anticoagulation (3-6 months). Recommended to NOT remove catheter if it is still functional and needed Initiate with UFH, LMWH, or fondaparinux then maintain with warfarin (INR 2-3) or LMWH Thrombolysis is generally NOT recommended but may be indicated for healthy patients (low risk of bleeding) with primary UEDVT with severe symptoms when appropriate expertise is available Surgical intervention is generally NOT recommended but may be indicated for patients with primary UEDVT who fail above therapy Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th 15 Edition). Chest 2008 Jun;133(6 Suppl):454S-545S.
6 Slide 16 Risk of Anticoagulation for DVT Major bleeding risk with warfarin for deep vein thrombosis Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism. Ann Intern Med 2003; 139: ,422 patients who received warfarin for more than 3 months Approximately 1 in 45 (2.2%) will experience a major bleeding episode Approximately 13% of these patients will die from the bleeding 16 Slide 17 Relationship Between Clot & Infection Stillman et al. Etiology of Catheter-associated sepsis: correlation with thrombogenicity. Arch Surg CVC were evaluated after removal 17 Slide 18 Relationship Between Clot & Infection Timsit et al. CVC-related thrombosis in ICU patients. CHEST IJ or SC catheters were analyzed Event Thrombosis No Thrombosis Significant CVC colonization 32% 19.4% CRS 19% 7% CR-septicemia 11.6% 3.6% Eastman et al. Central Venous Device-Related Infection and Thrombosis in Patients Treated with Moderate Dose Continuous-Infusion Interleukin-2. Cancer IJ or SC tunnelled catheters were analyzed Characteristic No. with CRBSI P value Device-related thrombosis Yes 8 (31%) <0.01 No 13 (10%)
7 Slide 19 Catheters and Thrombosis: Controllable Risk Factor Insertion site Femoral vein vs. Subclavian vein vs. Internal Jugular vein vs. PICC Catheter type, size, tip location Endothelial damage Traumatic insertion Tip location Catheter size and rigidity Venous stasis Catheter size relative to vein size Catheter material 19 Slide 20 Insertion Trauma Thrombosis Previous catheter and number of insertion attempts likely indicate endothelial damage: Odds ratio of 5.5 when 2 insertion Odds ratio of 3.8 with previous central catheter Agnes Y.Y. Lee et al. Incidence, Risk Factors, and Outcomes of Catheter-Related Thrombosis in Adult Patients With Cancer. Journal of Clinical Oncology Slide 21 Tip location Proximal tip may cause endothelial damage Luciani et al. CR UEDVT in Cancer Patients. Radiology patients with oropharyngeal CA with implantable CVC Tip confirmed with CXR then with monthly Doppler US Tip location divided into five segments 21 5% 8% 71% 42% 29%
8 Slide 22 Tip location Study Patients Thrombosis Kearns et al. JPEN patients with PICC; Central tip 16% central tip = in SVC Non-central 61% Grove & Pevec. JVIR 2000 Tesselaar et al. European J of Cancer PICC lines; symptomatic DVT 243 patients with implantable ports; symptomatic DVT Central tip 3.6% Non-central 9.3% 2.7x higher in SVC versus RA Lobo et al. Journal of Hospital Medicine PICC lines; symptomatic DVT/PE Non-central tip: OR 2.43 (95% CI ) 22 Slide 23 Stasis 23 Nifong TP, McDevitt TJ. The effect of catheter to vein ratio on blood flow rates in central venous catheters. CHEST. 2011;140(1):48-53 Slide 24 What does this mean clinically? Eastridge & Lefore J Clin Onc 1995 Trerotola SO, et al. Radiology Hickman catheters placed 279 SC and IJ tunneled catheters (Retrospective) Symptomatic DVT 10 Fr: 7.0% 12.5 Fr: 21% Symptomatic DVT Fr: 5.0% Fr: 12.7% p=0.027 Grove & Pevec. JVIR PICC lines (Retrospective) Symptomatic DVT 3 Fr: 0% 4 Fr: 1.0% p= Fr: 6.6% 6 Fr: 9.8% p= Allen et al. JVIR 2000 Trerotola et al Radiology 2010 Evans et al CHEST PICC lines Asymptomatic Cephalic: 57% (Retrospective) DVT Brachial: 10% Basilic: 14% 50 TLP (167 planned Symptomatic 20% 6 Fr tapered) in Total (A+S) 58%(27% extensive) Brachial or Basilic 2,014 PICCs in 1,879 Symptomatic DVT 4 Fr: 0.8% patients (Prospective) 5 Fr: 2.9% 6 Fr: 8.8%
9 Slide 25 What does this mean clinically? Evans et al. Risk of symptomatic DVT associated with peripherally inserted central catheters. CHEST Slide 26 Catheters and Thrombosis: Controllable Risk Factor Insertion site Femoral >> PICC > Subclavian vein Internal Jugular (lowest for HD) Catheter type, size, tip location Endothelial damage Traumatic insertion ( 2 attempts) Tip location (non-central >> atrial-caval junction) Catheter size and rigidity (large > small) Venous stasis Catheter size relative to vein size Catheter material 26 Slide Prevent Central Venous Catheter Infections (CR-BSI) 5 key components proposed by IHI-100K Hand hygiene Maximal barrier precautions Chlorhexidine skin antisepsis Optimal catheter site selection Daily review of line necessity + 4 interventions recommended by EPIC 2 Education of healthcare workers and patients Selection of catheter: lumens, tunnel, coated Catheter and site care General principles for catheter management + CVC insertion checklists Berenholtz Pronovost
10 Slide 28 Pronovost 2010 Prevent Central Venous Catheter Infections/CRI 5 key components proposed by IHI-100K Hand hygiene Maximal barrier precautions Chlorhexidine skin antisepsis Optimal catheter site selection Daily review of line necessity 28 BMJ 2010;340:c309 doi: /bmj.c309 Slide 29 Guidelines alone will not do the job Pratt, June 2010 WoCoVa Poor standards Wide variation in hospital practice Variable quality of practice Culture: 1. Do you have a champion at your hospital? 2. Do you have external drivers? 3. Do you track and report outcomes to all stakeholders? 4. Are team members empowered to stop a procedure if sterility is breached? 3-4X higher than U.S. 29 Slide 30 Pathogenesis of CRBSI 30
11 Slide 31 Our Goal 31 Slide 32 Infection Protection Technologies Evidence based recommendation by: Intervention Chlorhexidine Maximal Antimicrobial Antimicrobial Skin prep Barrier Dressing Catheter Source of Insertion (Biopatch TM, ) Transmission (e.g. AGB+ TM ) Environmental Yes Yes No No Contamination Skin Flora Yes Yes Yes No Subcutanous No No No Yes Tract (post placement) Hub/Intraluminal No No No Yes Hematogenous No No No Yes Seeding insertion procedure in situ 32 Slide 33 Multiple Strategies to Interrupt Infections Maximal Sterile Barrier Cap, mask, gown, gloves, drape Effective Prepping CHG/IPA Care and maintenance Education, hand hygiene, catheter & site selection, swabbing Dressings and Locks CHG Dressings & Add-on devices, dressing changes, Lock/flush solutions 33
12 % Reduction CRBSI Slide 34 Target zero: Support best practices Level 1 Level 2 Level 3 basic optimization new technology 34 Modified from Pittet D. Slide 35 The Catheter s Role in Interrupting Pathogenesis Additional Technologies Add layer of risk reduction Compliment other bundle layers Last layer of defense: Lapses in technique Compliance-fatigue Not implementing evidence-based practices Antimicrobial Catheters Designed to protect areas other bundle layers can t touch Subcutaneous tract Internal lumen Antimicrobial Catheter 35 Hematogenous Seeding Slide 36 CDC 2011 Category 1A recommendation Recommendation: use chlorhexidine/silver sulfadiazine or minocycline/rifampin impregnated CVC in patients whose catheter is expected to remain in place > 5 days if CLABSI has not been reduced by a comprehensive strategy: Educating persons who insert and care for catheters Use of maximal sterile barriers Use of a >0.5% chlorhexidine prep with alcohol for skin antisepsis during insertion Decision to use chlorhexidine/silver sulfadiazine or minocycline/rifampin impregnated CVC should be based on the need to reduce CLABSI rates, balanced against the concern for the emergence of resistant pathogens and the cost if implementing the strategy 36
13 Ultrasound, magnetics, EKG Slide 37 Catheters and Thrombosis: Controllable Risk Factor Insertion site Femoral >> PICC > Subclavian vein Internal Jugular (lowest for HD) Catheter type, size, tip location Endothelial damage Traumatic insertion ( 2 attempts) Tip location (non-central >> atrial-caval junction) Catheter size and rigidity (large > small) Venous stasis Catheter size relative to vein size Catheter material 37 Slide 38 Platelet Adhesion and Aggregation Vessel Wall Fibrinogen (GPIIbIIIa) Platelet Phospholipid Exterior Interior vwf (GPIb) Subendothelium 38 Slide 39 Central Venous Catheters Catheters provide a thrombogenic surface > Fibrin Sheath Endothelial damage Venous stasis STASIS VASCULAR INJURY 39
14 Slide 40 Fibrin Sheath Hoshal et al. Fibrin sleeve formation on indwelling subclavian CVC. Arch Surg subclavian veins with CVCs dissected at autopsy 100% had a fibrin sheath Materials: polyethylene, Teflon, nylon, siliconized rubber Raad et al JAMA 271(13) Additional radiographic studies show rates of 80-90% Sheath likely forms in first 24 hours Propagation of fibrin sheath originates from intimal injury at point of entry and at catheter tip 40 Slide 41 Catheter Materials Silicone Catheters: Medical grade silicone rubber has traditionally been considered the gold-standard for long-term vascular access in animals and humans. Its properties include: High biocompatibility Relatively non-thrombogenic Flexible Soft Polyurethane: Currently the material of choice. Its properties include: High biocompatibility Relatively non-thrombogenic Easier to insert sufficiently stiff but then softens in body Larger internal diameter compared to same silicone French size Increased flow rate due to increased lumen diameter 41 Slide 42 Platelet Adhesion and Aggregation Vessel Wall Fibrinogen (GPIIbIIIa) Platelet Phospholipid Exterior Interior 42 Thrombogenic surface
15 Slide 43 XI XII (Intrinsic Pathway) Acceleration XIa IX (Extrinsic Pathway) Initiation Tissue Injury Tissue Factor THE COAGULATION CASCADE IXa / VIIIa X Xa / Va X VIIa Crosslinked Fibrin XIIIa II Prothrombin Fibrin IIa Thrombin Fibrinogen 43 Slide 44 Pathogenesis of CR-DVT CR-DVT INSERTION TRAUMA ONGOING STASIS Thrombosis TIP LOCATION UNDERLYING HYPERCOAGULABILITY PLATELET ADHESION (ENDOTHELIUM & CATHETER) 44 Slide 45 Antithrombotic Materials: Current and Future Cook Medical: Heparin coating used to help prevent thrombus formation upon insertion Theoretical risk of HIT R4 Vascular: Biometric coating that resembles glycocalyx of healthy endothelial cells Claim: decrease intraluminal occlusion Teleflex: ArrowEVOLUTION with Chlorag+ard PENDING CLAIM (510K filed): antithrombogenic effect Navilyst: BioFlo products PENDING CLAIM (510K filed): minimizes the accumulation of thrombus in vascular products Semprus Biosciences: Covalent bonding of non-leaching material that simulates endothelial cell membrane; pre-clinical 45
16 Slide 46 Pathogenesis of CRBSI INFECTION INFECTIOUS AGENT SUSCEPTIBLE HOST CHAIN OF INFECTION PORTAL OF ENTRY ATTACHMENT and COLONIZATION 46 Meakins JL, Masterson BJ. Prevention of postoperative infection. ACS Surgery Slide 47 Coated Catheters Carrasco et al. Evaluation of a triple-lumen CV heparin-coated catheter versus a catheter coated with chlorhexidine and silver sulfadiazide in critically ill patients. Int Care Med patients (260 catheters) randomized to receive either CVC Heparin coated (132 catheters): Colonization 23.5/1,000 catheter days CR-BSI 3.2/1,000 catheter days CSS Colonization 11.5/1,000 catheter days CR-BSI 2.6/1,000 catheter day 47 Slide 48 Summary Key Points > CR-BSI and CR-thrombosis are both significant complications of central venous access > Prevention is the Goal > Technology-driven solutions are required to further reduce the risk to patients > Right Care, Right Now (for the) Right Patient > Make a Business case issue for Hospital Administrators > Quality Care with Improved Outcomes 48
17 Slide 49 Thank you for your attention!
Nuovi materiali per la prevenzione di infezione e trombosi: quali evidenze?!
Nuovi materiali per la prevenzione di infezione e trombosi: quali evidenze?! Massimo Lamperti MD, MBA! Clinical Professor of Anesthesiology! Cleveland Clinic Lerner College of Medicine! Chief of General
More informationCatheter-Related Thrombosis A Catalyst of Complications
Catheter-Related Thrombosis A Catalyst of Complications Catheter-Related Occlusions 1,2 Most common non-infectious complication in the long-term use of CVCs, and in particular PICCs Approximately 1 in
More informationReaching New Heights in Understanding Central Venous Catheter Thrombosis
Reaching New Heights in Understanding Central Venous Catheter Thrombosis Lynn Manly, RN, CRNI, VA BC, Clinical Director, Navilyst Medical, Tarpon Springs, FL Top 4 Things to Know for CE 1. Make sure your
More informationReaching New Heights in Understanding Central Venous Catheter Thrombosis
Reaching New Heights in Understanding Central Venous Catheter Thrombosis Lynn Manly, RN, CRNI, VA BC, Clinical Director, Navilyst Medical, Tarpon Springs, FL Top 4 Things to Know for CE 1. Make sure your
More informationNavigating Vascular Access Issues
Navigating Vascular Access Issues The Oley Foundation 27 th Annual Consumer/Clinician Conference Redondo Beach, CA June, 27 2012 Anita Piano, BS, RN, VA-BC Administrative Nurse, PICC Service UCLA Health
More informationClinical Practice Guideline on Central Venous Catheter Care for the Patient with Cancer
Clinical Practice Guideline on Central Venous Catheter Care for the Patient with Cancer COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER
More informationPrevention of thrombosis
Prevention of thrombosis Massimo Lamperti MD, MBA Chief of General Anaesthesia Department Anaesthesiology Institute Cleveland Clinic Abu Dhabi Clinical Professor of Anaesthesiology Cleveland Clinic Lerner
More informationDVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center
DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the
More informationTHROMBOTIC DISORDERS: The Final Frontier
THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.
More informationIdentification and Management of Central Vascular Access Device Complications
Identification and Management of Central Vascular Access Device Complications David Hahn, MD Interventional Radiology NorthShore University HealthSystem Evanston, Illinois Disclosures Consultant, AngioDynamics,
More informationPort Design. Page 1. Port Placement, Removal, and Management. Selecting a Vascular Access Device. Thomas M. Vesely, MD
Non-Dialysis Procedures Port Placement, Removal, and Management Thomas M. Vesely, MD Saint Louis, Missouri Selecting a Vascular Access Device Duration of use Number of lumens Frequency used Blood flow
More informationCentral Venous Catheter (CVC) Care for the Patient with Cancer. Clinical Practice Guideline
Central Venous Catheter (CVC) Care for the Patient with Cancer Clinical Practice Guideline Introduction & Context Stable venous access is used for a wide range of indications including chemotherapy, blood
More informationESPEN Congress Florence 2008
ESPEN Congress Florence 2008 Complications of Central Venous Catheters EPIDEMIOLOGY & DIAGNOSIS & PREVENTION Federico Bozzetti (Italy) CVC COMPLICATIONS EPIDEMIOLOGY & DIAGNOSIS & PREVENTION Federico Bozzetti
More information4/23/2009. September 15, 2008
The Current Treatment of Deep Venous Thrombosis: Are We Doing Enough? George H. Meier, MD Professor and Chief Division of Vascular Surgery University of Cincinnati College of Medicine Cincinnati, Ohio
More informationThe University of Toledo Medical Center and its Medical Staff
Name of Policy: Policy Number: Department: 3364-109-GEN-705 Infection Control Medical Staff Hospital Administration Approving Officer: Responsible Agent: Scope: Chair, Infection Control Committee Chief
More informationAmerican College of Surgeons Critical Care Review Course 2012: Infection Control
American College of Surgeons Critical Care Review Course 2012: Infection Control Overview: I. Central line associated blood stream infection (CLABSI) II. Ventilator associated pneumonia (VAP) I. Central
More informationCentral Line-Associated Infections (CLABSI) Settings Toolkit
Central Line-Associated Infections (CLABSI) in Non-Intensive Care Unit (non-icu) Settings Toolkit Activity C: ELC Prevention Collaboratives Alex Kallen, MD, MPH and Priti Patel, MD, MPH Division of Healthcare
More informationThrombosis: The Other Central Venous Catheter Complication
Thrombosis: The Other Central Venous Catheter Complication The Thrombosis-Infection Relationship Cheryl Kelley RN BSN, VA-BC Sr. Vascular Access Clinical Specialist Disclosure Employed by Teleflex Medical
More informationInherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD
Inherited Thrombophilia Testing George Rodgers, MD, PhD Kristi Smock MD Prevalence and risk associated with inherited thrombotic disorders Inherited Risk Factor % General Population % Patients w/ Thrombosis
More informationLow Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders
SURGICAL GRAND ROUNDS March 17 th, 2007 Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders Guillermo Escobar, M.D. LMWH vs UFH Jayer s sales pitch: FALSE LMW is
More informationVascular access in practice: best practice update
Vascular access in practice: best practice update Nicola York Clinical Nurse Manager Vascular Access Oxford University Hospitals NHS Foundation Trust June 2016 Objectives Patient assessment Best practice
More informationDisclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None
Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)
More informationVenous Thrombo-Embolism. John de Vos Consultant Haematologist RSCH
Venous Thrombo-Embolism John de Vos Consultant Haematologist RSCH overview The statistics Pathogenesis Prophylaxis Treatment Agent Duration Incidental VTE Recurrence of VTE IVC filters CVC related thrombosis
More informationPrevention of Central Line-associated Bloodstream Infections (CLA-BSIs) associated with Arterial Catheters
Prevention of Central Line-associated Bloodstream Infections (CLA-BSIs) associated with Arterial Catheters William R. Jarvis, M.D. President, Jason and Jarvis Associates, LLC Saxe Communications 2012 Sponsored
More informationCentral Venous Access Devices and Infection
Central Venous Access Devices and Infection Dr Andrew Daley Microbiology & Infectious Diseases Women s & Children s Health Melbourne Background Types of infection! Local site infection! Blood stream infection!
More informationA Review of Guidelines and Recommendations on the Prevention of Catheter-related Infections
A Review of Guidelines and Recommendations on the Prevention of Catheter-related Infections Houston Chapter Association for Professionals in Infection Control and Epidemiology, Inc. Houston, Texas February
More informationPreventing Central Venous Catheter Complications- An evidence based approach
Preventing Central Venous Catheter Complications- An evidence based approach Srinivas Bapoje MD, MPH Director, Hospital Medicine Procedure Service Denver Health Medical Center Learning Objectives Discuss
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationPROGNOSIS AND SURVIVAL
CANCER ASSOCIATED THROMBOSIS PROGNOSIS AND SURVIVAL Since French internist Armand Trousseau reported the occurrence of mysterious thrombotic disorders in cancer patients in the mid-19th century, the link
More informationA Primer on Central Venous Access: Peripherally-Inserted Central Catheters, Tunneled Catheters, and Subcutaneous Ports
Disclosures A Primer on Central Venous Access: Peripherally-Inserted Central Catheters, Tunneled Catheters, and Subcutaneous Ports No conflicts of interest relevant to this presentation Jason W. Pinchot,
More informationCentral Line Care and Management
Central Line Care and Management What is a Central Line/ CVAD? (central venous access device) A vascular infusion device that terminates at or close to the heart or in one of the great vessels (aorta,
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationA Comparative Evaluation of Antimicrobial Coated versus Non-antimicrobial
A Comparative Evaluation of Antimicrobial Coated versus Non-antimicrobial Coated Peripherally Inserted Central Catheters on Associated Outcomes: A Randomized Controlled Trial. Susan Storey, PhD, RN; Jamie
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationVascular Access Options for Apheresis Medicine
Vascular Access Options for Apheresis Medicine Josh King, MD Divisions of Nephrology and Medical Toxicology University of Virginia September 21, 2018 Disclosure I have no personal or professional financial
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationPulmonary Thromboembolism
Pulmonary Thromboembolism James Allen, MD Epidemiology of Pulmonary Embolism 1,500,000 new cases per year in the United States Often asymptomatic 300,000 deaths per year DVT or PE present in 10% of ICU
More informationIntervention Training Groningen
Intervention Training Groningen Evidence-based practice to reduce CVC-related infections Outline Background Technology Best practice Summary Outline Background Technology Best practice Summary Sources
More informationEpidemiology of Thrombosis in Patients with Malignancy. Cancer and Venous Thromboembolism. Chew HK, Arch Int Med, Feb Blom et al, JAMA, Feb 2005
Cancer and Venous Thromboembolism Objectives 1. Epidemiology of thrombosis in patients with malignancy 2. Anticancer agents and thrombosis 3. Current treatment protocols at UHN 4. Prevention of DVT 5.
More informationPrimary Exam Physiology lecture 5. Haemostasis
Primary Exam Physiology lecture 5 Haemostasis Haemostasis Body s response for the prevention and cessation of bleeding. Broadly consists of: Primary Haemostasis - vascular spasm and platlet plug formation
More informationResearch Article The Incidence of Peripheral Catheter-Related Thrombosis in Surgical Patients
rombosis Volume 2016, Article ID 6043427, 6 pages http://dx.doi.org/10.1155/2016/6043427 Research Article The Incidence of Peripheral Catheter-Related Thrombosis in Surgical Patients Amy Leung, 1,2,3 Clare
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationCURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow
CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM Gordon Lowe Professor of Vascular Medicine University of Glasgow VENOUS THROMBOEMBOLISM Common cause of death and disability 50% hospital-acquired
More informationBloodstream Infections
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 30: Bloodstream Infections Authors Larry Lutwick MD Gonzalo Bearman MD, MPH Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Topic Outline Definition
More informationUltrasound Guided Vascular Access. 7/25/2016
Ultrasound Guided Vascular Access 7/25/2016 www.ezono.com 1 Objectives Indications for insertion of central and peripheral lines Complications associated with procedures Role of ultrasound in vascular
More informationVenous Thromboembolism Prophylaxis: Checked!
Venous Thromboembolism Prophylaxis: Checked! William Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University of Toronto National Lead, VTE Prevention, Safer
More informationCancer Associated Thrombosis An update.
Cancer Associated Thrombosis An update. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway LIQUID
More informationAV ACESS COMPLICATIONS. Ass. Prof. Dr. Habas
AV ACESS COMPLICATIONS Ass. Prof. Dr. Habas COMPLICATION AVF IS CONSIDERED A MINOR PROCEDURE INCIDENCE OF COMPLICATION- 20-27% MANY A COMPLICATION LEADS TO FAILURE OF FISTULA LOSS OF SITE AND VEIN FOR
More informationClinical Study Is There Any Association between PEEP and Upper Extremity DVT?
Critical Care Research and Practice Volume 2015, Article ID 614598, 5 pages http://dx.doi.org/10.1155/2015/614598 Clinical Study Is There Any Association between PEEP and Upper Extremity DVT? Farah Al-Saffar,
More informationUnderstanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal
Understanding thrombosis in venous thromboembolism João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Disclosures João Morais On the last year JM received honoraria
More informationOverview of CVADs. Type of device commonly used. Dwell time Flushing requirement Associated complications. lumens
Source: Clinical Skills Management of Vascular Access Devices Pre-course handbook. Adapted with permission from NHS Lothian Employee and Education Development Team. Overview of CVADs Type of device Veins
More informationYou have a what, inside you?
Costal Emergency Medicine Conference You have a what, inside you? Less than mainstream medical devices encountered in the ED. Eric Ossmann, MD, FACEP Associate Professor Duke University Medical Center
More informationCatheter Vessel Ratio : Now What?
Catheter Vessel Ratio : Now What? Timothy R Spencer, DipAppSc, BHealth, IC Cert, RN, APN, VA-BCTM Keegan J Mahoney, BS, RRT, VA-BCTM Vascular Access Specialist, Global Vascular Access, Scottsdale AZ Vascular
More informationCentral venous catheters
Follow the link from the online version of this article to obtain certified continuing medical education credits Central venous catheters Reston N Smith, 1 Jerry P Nolan 2 1 North Bristol NHS Trust, Bristol,
More informationThrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI
Thrombophilia Diagnosis and Management Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri
More informationVTE in Children: Practical Issues
VTE in Children: Practical Issues Wasil Jastaniah MBBS,FAAP,FRCPC Consultant Pediatric Hem/Onc/BMT May 2012 Top 10 Reasons Why Pediatric VTE is Different 1. Social, ethical, and legal implications. 2.
More informationApproach to Thrombosis
Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation
More informationRisk Factor Evaluation for Thrombosis and Bleeding in Pediatric Patients with Heart Disease
Risk Factor Evaluation for Thrombosis and Bleeding in Pediatric Patients with Heart Disease Kristen Nelson, MD Johns Hopkins University Director, Pediatric Cardiac Critical Care Why Does it Matter? Pediatric
More informationPreventing CLABSI & CAUTI Preventive Measures for Central Line Associated Bloodstream Infection & Catheter Associated UTI
Preventing CLABSI & CAUTI Preventive Measures for Central Line Associated Bloodstream Infection & Catheter Associated UTI Kaiser Permanente For Internal use only Objectives By the end of this lesson, you
More informationHandbook for Venous Thromboembolism
Handbook for Venous Thromboembolism Gregory Piazza Benjamin Hohlfelder Samuel Z. Goldhaber Handbook for Venous Thromboembolism Gregory Piazza Cardiovascular Division Harvard Medical School Brigham and
More informationSlide 1. Slide 2. Slide 3. Outline of This Presentation
Slide 1 Current Approaches to Venous Thromboembolism Prevention in Orthopedic Patients Hujefa Vora, MD Maria Fox, RN June 9, 2017 Slide 2 Slide 3 Outline of This Presentation Pathophysiology of venous
More informationThe risk of venous thromboembolism associated with peripherally inserted central catheters in ambulant cancer patients
Jones et al. Thrombosis Journal (2017) 15:25 DOI 10.1186/s12959-017-0148-y RESEARCH Open Access The risk of venous thromboembolism associated with peripherally inserted central catheters in ambulant cancer
More informationCANCER ASSOCIATED THROMBOSIS. Pankaj Handa Department of General Medicine Tan Tock Seng Hospital
CANCER ASSOCIATED THROMBOSIS Pankaj Handa Department of General Medicine Tan Tock Seng Hospital My Talk Today 1.Introduction 2. Are All Cancer Patients at Risk of VTE? 3. Should All VTE Patients Be Screened
More informationYou have a what, inside you?
Costal Emergency Medicine Conference You have a what, inside you? Less than mainstream medical devices encountered in the ED. Eric Ossmann, MD, FACEP Associate Professor Duke University Medical Center
More informationSupplementary Online Content
Supplementary Online Content Mismetti P, Laporte S, Pellerin O, Ennezat P-V, Couturaud F, Elias A, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone
More informationIliofemoral DVT: Miminizing Post-Thrombotic Syndrome
Iliofemoral DVT: Miminizing Post-Thrombotic Syndrome Catherine K. Chang, MD FACS Vascular Surgery San Diego Southern California Permanente Medical Group Acute Deep Venous Thrombosis Incidence & Outcomes
More informationFrequently Asked Questions about Cancer Associated Thrombosis
+ Frequently Asked Questions about Cancer Associated Thrombosis Atlantic Canada Oncology Group Annual Meeting June 13 th, 2015 Sudeep Shivakumar, Dalhousie University + Conflict of Interest Disclosures
More informationIV therapy. By: Susan Mberenga, RN, MSN. Copyright 2016, 2013, 2010, 2006, 2002 by Saunders, an imprint of Elsevier Inc.
IV therapy By: Susan Mberenga, RN, MSN 1 IV Therapy Types of solutions Isotonic Hypotonic Hypertonic Caution: Too rapid or excessive infusion of any IV fluid has the potential to cause serious problems
More informationMary Lou Garey MSN EMT-P MedFlight of Ohio
Mary Lou Garey MSN EMT-P MedFlight of Ohio Function Prolonged and frequent access to venous circulation Allows for patient to carry on normal life; decrease number of needle sticks Medications, parenteral
More informationOsamah Al-Asadi 1,2,3*, Manar Almusarhed 1,2,4 and Hany Eldeeb 1,2
Al-Asadi et al. Thrombosis Journal (2019) 17:2 https://doi.org/10.1186/s12959-019-0191-y REVIEW Predictive risk factors of venous thromboembolism (VTE) associated with peripherally inserted central catheters
More informationReducing Risk in Vascular Access: A Review of Best Practice. Timothy R. Spencer, RN, APN, DipAppSci, Bach.Health, ICCert, VA-BC
Reducing Risk in Vascular Access: A Review of Best Practice Timothy R. Spencer, RN, APN, DipAppSci, Bach.Health, ICCert, VA-BC Why are we here tonight? Majority of CLABSI occurs outside the ICU Central
More informationCancer and Thrombosis
Cancer and Thrombosis The close relationship between venous thromboembolism and cancer has been known since at least the 19th century by Armand Trousseau. Thrombosis is a major cause of morbidity and mortality
More informationPrevent Bloodstream Infections by Using Appropriate Devices
37 Prevent Bloodstream Infections by Using Appropriate Devices Situation Catheter-associated infections include exit, tunnel, pocket and bloodstream infections. In the United States, when these types of
More informationCharacterizing resolution of catheter-associated upper extremity deep venous thrombosis
Characterizing resolution of catheter-associated upper extremity deep venous thrombosis Mark A. Jones, MD, a Dae Y. Lee, MD, b Jocelyn A. Segall, MD, c Gregory J. Landry, MD, b Timothy K. Liem, MD, b Erica
More informationNew oral anticoagulants and Palliative Care.
New oral anticoagulants and Palliative Care. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway
More informationJessica Bryan, Natalia Evans, Karlyn Henderson, & Whitney Parks
Jessica Bryan, Natalia Evans, Karlyn Henderson, & Whitney Parks 1. What is the most common cause of death in hospitalized patients? 1. Hospital-acquired infection 2. Pulmonary embolism 3. Myocardial infarction
More informationESPEN Congress Brussels How to take care of central venous access devices (CVAD)? Eva Johansson
ESPEN Congress Brussels 2005 How to take care of central venous access devices (CVAD)? Eva Johansson How to take care of central venous access devices (CVAD)? Eva Johansson, RN, PhD Division of Hematology
More informationFactor Xa Inhibition in the Management of Venous Thromboembolism: Important Safety Information. Important Safety Information (cont d)
Factor Xa Inhibition in the Management of Venous Thromboembolism: The Role of Fondaparinux WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with
More informationClinical Nutrition 28 (2009) Contents lists available at ScienceDirect. Clinical Nutrition
Clinical Nutrition 28 (2009) 365 377 Contents lists available at ScienceDirect Clinical Nutrition journal homepage: http://www.elsevier.com/locate/clnu ESPEN Guidelines on Parenteral Nutrition: Central
More informationVenous Thrombosis. Magnitude of the Problem. DVT 2 Million PE 600,000. Death 60,000. Estimated Cost of VTE Care $1.5 Billion/year.
Venous Thrombosis Magnitude of the Problem DVT 2 Million Postthrombotic Syndrome 800,000 PE 600,000 Death 60,000 Silent PE 1 Million Pulmonary Hypertension 30,000 Estimated Cost of VTE Care $1.5 Billion/year
More informationVenous Thromboembolism (VTE) in Myeloma. Christine Chen May 2017
Venous Thromboembolism (VTE) in Myeloma Christine Chen May 2017 Objectives 1. Review the magnitude of the problem and why myeloma patients are at risk of VTE 2. Discuss thromboprophylaxis approaches in
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationUpper Extremity Venous Duplex. Michigan Sonographers Society Fall Ultrasound Symposium October 15, 2016
Upper Extremity Venous Duplex Michigan Sonographers Society Fall Ultrasound Symposium October 15, 2016 Patricia A. (Tish) Poe, BA RVT FSVU Director of Quality Assurance Navix Diagnostix Patricia A. Poe
More informationVascular access device selection & placement. Alisa Seangleulur, MD Anesthesiology Department, Faculty of Medicine, Thammasat University
Vascular access device selection & placement Alisa Seangleulur, MD Anesthesiology Department, Faculty of Medicine, Thammasat University How to make the right choice of vascular access device.. Peripheral
More informationInterventional Treatment VTE: Radiologic Approach
Interventional Treatment VTE: Radiologic Approach Hae Giu Lee, MD Professor, Dept of Radiology Seoul St. Mary s Hospital The Catholic University of Korea Introduction Incidence High incidence: 250,000-1,000,000/year
More informationPICC, port e trombosi cateterecorrelata: la prevenzione è legata alla tecnica di impianto!
PICC, port e trombosi cateterecorrelata: la prevenzione è legata alla tecnica di impianto! Massimo Lamperti MD, MBA! Clinical Professor of Anesthesiology! Cleveland Clinic Lerner College of Medicine! Chief
More informationThe legally binding text is the original French version. Opinion 15 May 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 15 May 2013 ARIXTRA 2.5 mg/0.5 ml, solution for injection in pre-filled syringe B/2 (CIP: 34009 359 225 4 0) B/7 (CIP:
More informationUC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE
Updates in the Management of Venous Thromboembolism Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic Venous Thromboembolism
More informationCurrent issues in the management of Superficial Vein Thrombosis - SVT
Current issues in the management of Superficial Vein Thrombosis - SVT Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Faculty of Medicine, School of Health Sciences,
More informationA Brief History of the World of Anticoagulation
A Brief History of the World of Anticoagulation Allison Burnett, PharmD, CACP, PhC Clinical Assistant Professor- UNM College of Rx Antithrombosis Stewardship Pharmacist University of New Mexico Hospital
More informationSuccessful IV Starts Revised February 2014
Successful IV Starts Revised February 2014 Why Intravenous Therapy? Used for access to the body s circulation Indications: Administer fluids, blood, medications, and nutrition Obtain laboratory specimens
More informationCVAD Selection and Tip Placement Overcoming Controversies with Evidence
CVAD Selection and Tip Placement Overcoming Controversies with Evidence Scott O. Trerotola, MD Stanley Baum Professor of Radiology and Surgery Chief, Vascular and Interventional Radiology University of
More informationAppendix E: Overview of Vascular
Appendix E: Overview of Vascular 56 Peripheral Short Catheter, less than 3 inches (7.5 cm) in length; over-the-needle catheter is most common. Inserted by percutaneous venipuncture, generally into a hand
More informationStuck dialysis catheters. ANZSIN 2013 Michael Lam & Kendal Redmond
Stuck dialysis catheters ANZSIN 2013 Michael Lam & Kendal Redmond NT 39 yr old CI Maori - ESKD 2 o to cortical necrosis HD August 2002 R IJ tunneled Tesio catheter Oct 2002 Failed L RC AVF Feb 2004 Failed
More informationObjectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?
Objectives Venous Thromboembolism (VTE) Prophylaxis Rishi Garg, MD Department of Medicine Identify patients at risk for VTE Options for VTE prophylaxis Current Recommendations (based on The Seventh ACCP
More informationLifecath Twin & Dualyse/Trilyse Permanent and Temporary Renal Catheters
Lifecath Twin & Dualyse/Trilyse Permanent and Temporary Renal Catheters Accurate locking dose Excellent flow rates Safe connections vygon@vygon.co.uk www.vygon.co.uk Product Information Product Information
More information2011 CDC Guidelines for the Prevention of Intravascular Catheter-Associated Infections
2011 CDC Guidelines for the Prevention of Intravascular Catheter-Associated Infections Strategies to Reduce Intravascular Catheter-Associated Infections George Allen, PhD, CIC, CNOR Dr. Allen is a paid
More informationThe Impact of Catheter Occlusion in Central Line Associated Bloodstream Infections M A R C H 15, 2017
The Impact of Catheter Occlusion in Central Line Associated Bloodstream Infections D A R C Y DOELLMAN M S N, RN, CRNI, VA - BC M A R C H 15, 2017 LOUISVILLE, KENTUCKY Cincinnati Children s Hospital 642
More informationHEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the investigation and management of suspected and documented heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a transient,
More information